Hydrochloric Acid → HCID 136366929, Verbindung

Reaktionsgleichung

[OH:1][C@H:2]([CH2:29][CH:30]([CH3:32])[CH3:31])[C:3]([N:5]1[CH2:10][CH2:9][N:8]([C:11]2[C:20]3[C:15](=[CH:16][C:17]([CH3:21])=[CH:18][CH:19]=3)[N:14]=[C:13]([C:22]3[CH:27]=[CH:26][CH:25]=[CH:24][C:23]=3[OH:28])[N:12]=2)[CH2:7][CH2:6]1)=[O:4].[ClH:33].CCOCC>C(Cl)Cl>[ClH:33].[OH:1][C@H:2]([CH2:29][CH:30]([CH3:32])[CH3:31])[C:3]([N:5]1[CH2:10][CH2:9][N:8]([C:11]2[C:20]3[C:15](=[CH:16][C:17]([CH3:21])=[CH:18][CH:19]=3)[N:14]=[C:13]([C:22]3[CH:27]=[CH:26][CH:25]=[CH:24][C:23]=3[OH:28])[N:12]=2)[CH2:7][CH2:6]1)=[O:4]

Komponenten

Versuchsvorschrift

(R)-2-hydroxy-1-(4-(2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl)piperazin-1-yl)-4-methylpentan-1-one (90 mg, 0.20 mmol) was dissolved in 1 mL CH2Cl2 and treated with 1 equivalent of 2.0 M HCl in ether (100 μL, 0.20 mmol). The formed precipitate was filtered and vacuum dried to obtain (R)-2-hydroxy-1-(4-(2-(2-hydroxyphenyl)-7-methylquinazolin-4-yl)piperazin-1-yl)-4-methylpentan-1-one hydrochloride. LC/MS: m/z 435.1 (M+H)+ at 2.84 min (10%-99% CH3CN (0.035% TFA)/H2O (0.05% TFA)). 1H NMR (400 MHz, CD3OD) δ 8.39-8.37 (m, 1H), 8.18 (d, J=8.6 Hz, 1H), 7.78 (s, 1H), 7.61-7.55 (m, 2H), 7.15-7.11 (m, 2H), 4.57 (dd, J=9.5, 3.5 Hz, 1H), 4.49-4.32 (m, 4H), 4.07-3.79 (m, 4H), 2.62 (s, 3H), 1.97-1.87 (m, 1H), 1.65-1.58 (m, 1H), 1.53-1.47 (m, 1H), 1.03-1.00 (m, 6H).